Peptide Synthesis Company Activotec completes new funding round
14-Jan-2008
Activotec chief executive, Chris Littlewood, commented: "The funds will be invested in expanding our research and development as well as new personnel and premises. This will assist us in our dual strategy of accelerating our peptide synthesiser development and sales as well as leveraging our innovative peptide technology through collaborative projects with biotechnology and pharmaceutical partners to develop new peptide therapeutics."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.